Achieve Life Sciences Inc.
Organization details
- Legal name
- Achieve Life Sciences Inc.
- Former names
- Oncogenex Pharmaceuticals, INC. Sonus Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- QUIT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000949858
- EIN
- 95-4343413
Board of directors
-
Aaron Royston · DirectorSince 2026
-
Andrew D. Goldberg · Director · CEO and PresidentSince 2026
-
Bridget A. Martell · DirectorSince 2023
-
Christopher Nathan Martin · DirectorSince 2026
-
Cindy Jacobs · Director · President & CMOSince 2023
-
Jeffrey S. Farrow · DirectorSince 2026
-
John Bencich · Director · CEOSince 2023
-
Kristen B. Slaoui · DirectorSince 2025
-
Lucian Iancovici · DirectorSince 2026
-
Nancy R. Phelan · DirectorSince 2025
-
Reid Alexander Waldman · DirectorSince 2026
-
Richard Alistair Stewart · Director · Chief Executive OfficerSince 2023
-
Stuart Duty · DirectorSince 2023
-
Thomas Braxton King · Director · Executive ChairmanSince 2023
-
Thomas Sellig · DirectorSince 2023
-
Vaughn B. Himes · DirectorSince 2023
Chief executives
Director election results
Annual meeting of July 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.8%
-
95.8%
-
98.4%
-
98.7%
-
99.5%
-
99.5%
-
99.5%
-
99.5%
-
99.6%
Board connections
7 of this board's directors also sit on 12 other boards. 11 are in the same sector.
-
Aligos Therapeutics Inc. Same sectorvia Bridget A. Martell
-
Attovia Therapeutics Inc. Same sectorvia Aaron Royston
-
CeriBell Inc. Same sectorvia Lucian Iancovici
-
Delcath Systems Inc. Same sectorvia Bridget A. Martell
-
Edgewise Therapeutics Inc. Same sectorvia Christopher Nathan Martin
- via Stuart Duty
-
Foghorn Therapeutics Inc. Same sectorvia Stuart Duty
-
Milestone Pharmaceuticals Inc. Same sectorvia Stuart Duty
-
Oruka Therapeutics Inc. Same sectorvia Christopher Nathan Martin
-
Sionna Therapeutics Inc. Same sectorvia Lucian Iancovici
-
Tarsus Pharmaceuticals Inc. Same sectorvia Andrew D. Goldberg
-
Veradermics Incorporated Same sectorvia Reid Alexander Waldman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $175,115
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Richard Alistair Stewart Director | Open-market sale | −20,626 | $8.49 | $175,115 |
| Sep 18, 2025 | Oki Mark K Officer (Chief Financial Officer) | Option exercise | +168,000 | — | — |
| Sep 18, 2025 | Richard Alistair Stewart Director, Officer (Chief Executive Officer) | Option exercise | +297,500 | — | — |
| Sep 18, 2025 | Oki Mark K Officer (Chief Financial Officer) | Open-market sale | −50,060 | $2.92 | $146,175 |
| Sep 18, 2025 | Richard Alistair Stewart Director, Officer (Chief Executive Officer) | Open-market sale | −129,501 | $2.92 | $378,143 |
| Sep 4, 2025 | Wan Jerry Officer (Principal Accounting Officer) | Option exercise | +34,100 | — | — |
| Sep 4, 2025 | Thomas Braxton King Director | Option exercise | +455,000 | — | — |
| Sep 4, 2025 | Cindy Jacobs Officer (President & CMO) | Option exercise | +110,000 | — | — |
| Sep 4, 2025 | Xinos Jaime Officer (Chief Commercial Officer) | Option exercise | +69,000 | — | — |
| Sep 4, 2025 | Wan Jerry Officer (Principal Accounting Officer) | Open-market sale | −14,070 | $2.77 | $38,974 |
| Sep 4, 2025 | Thomas Braxton King Director | Open-market sale | −139,858 | $2.77 | $387,407 |
| Sep 4, 2025 | Cindy Jacobs Officer (President & CMO) | Open-market sale | −27,629 | $2.77 | $76,532 |
| Sep 4, 2025 | Xinos Jaime Officer (Chief Commercial Officer) | Open-market sale | −20,854 | $2.77 | $57,766 |
| Mar 17, 2025 | Oki Mark K Officer (Chief Financial Officer) | Open-market purchase | +10,000 | $2.89 | $28,900 |
| Mar 17, 2025 | Richard Alistair Stewart Director, Officer (Chieve Executive Officer) | Open-market purchase | +10,000 | $2.86 | $28,600 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Achieve Life Sciences Inc.
Who is the CEO of Achieve Life Sciences Inc.?
Andrew D. Goldberg has been Achieve Life Sciences Inc.'s CEO and President since April 2026.
How many directors are on Achieve Life Sciences Inc.'s board?
Achieve Life Sciences Inc.'s board has 16 directors: Aaron Royston, Andrew D. Goldberg, Bridget A. Martell, Christopher Nathan Martin, Cindy Jacobs, Jeffrey S. Farrow, John Bencich, Kristen B. Slaoui, Lucian Iancovici, Nancy R. Phelan and 6 others.
Are Achieve Life Sciences Inc. insiders buying or selling shares?
Over the last 12 months, Achieve Life Sciences Inc. insiders made no open-market purchases and sold $175,115 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="achieve-life-sciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.